Urinary and rectal incontinence during gabapentin therapy.
Iyer
Renuka
R
Egloff
Lori
L
Fraas
Jamie
J
Harris
Juan-Diego
JD
D000368:Aged; D000588:Amines / Q000009:adverse effects* / Q000627:therapeutic use; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D003509:Cyclohexanecarboxylic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D005242:Fecal Incontinence / Q000139:chemically induced*; D005260:Female; D000077206:Gabapentin; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D010146:Pain / Q000188:drug therapy; D014549:Urinary Incontinence / Q000139:chemically induced*; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects* / Q000627:therapeutic use
D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin